13404-22-3

Basic information

• Product Name: tert-Butyl L-alaninate hydrochloride
• Synonyms: ALANINE-OTBU HCL;L-ALANINE T-BUTYL ESTER HYDROCHLORIDE;L-ALANINE T-BUTYL ESTER HYDROCHLORIDE SALT;L-ALANINE TERT-BUTYL ESTER HYDROCHLORIDE;L-ALA-T-BUTYL ESTER HCL;H-ALA-OBUT HCL;H-ALA-OTBU HCL;H-ALA-OTBU HYDROCHLORIDE
• CAS NO: 13404-22-3
• Molecular Formula: C₇H₁₅NO₂*ClH
• Molecular Weight: 181.66
• EINECS: 236-497-8
• Product Categories: Amino Acids Derivatives;Amino Acids;Alanine [Ala, A];Amino Acids and Derivatives;Amino Acid tert-Butyl Esters;Amino Acids (C-Protected);Biochemistry;Amino hydrochloride;A - HPeptide Synthesis;Alanine;Amino Acid Derivatives;Amino Acids;Modified Amino Acids;Peptide Synthesis;amino
• Mol File: 13404-22-3.mol

Chemical Properties

• Melting Point: 168-175 °C (dec.)
• Boiling Point: 163.1 °C at 760 mmHg
• Flash Point: 37 °C
• Appearance: White to off-white/Solid or Crystalline Powder
• Vapor Pressure: 2.1mmHg at 25°C
• Refractive Index: 2.0 ° (C=2, EtOH)
• Storage Temp.: 2-8°C
• Solubility: Soluble in methanol.
• Sensitive: Hygroscopic
• BRN: 3562140
• CAS DataBase Reference: tert-Butyl L-alaninate hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl L-alaninate hydrochloride(13404-22-3)
• EPA Substance Registry System: tert-Butyl L-alaninate hydrochloride(13404-22-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 22-24/25-36-26
• WGK Germany: 3
• Hazardous Substances Data: 13404-22-3(Hazardous Substances Data)

Usage

Chemical Properties

Crystalline powder

Uses

It is used as a pharmaceutical intermediate.

InChI:InChI=1/C7H15NO2.ClH/c1-5(8)6(9)10-7(2,3)4;/h5H,8H2,1-4H3;1H/t5-;/m0./s1

Upstream product

• 50300-96-4 (S)-2-(benzyloxycarbonylamino)propionic acid tert-butyl ester 
• 540-88-5 acetic acid tert-butyl ester 
• 56-41-7 L-alanin 
• 58177-77-8 N-[(1,1-dimethylethoxy)carbonyl]-L-alanine 1,1-dimethylethyl ester 

Downstream Products

• 80828-28-0 N-<(R)-1-(ethoxycarbonyl)-3-phenylpropyl>-L-alanine tert-butylester 
• 80828-38-2 N-<(S)-1-(ethoxycarbonyl)-3-phenylpropyl>-L-alanine tert-butylester 
• 84758-69-0 Z-Aib-L-Ala-OtBu 
• 33033-71-5 (S)-tert-butyl 2-((S)-2-(((benzyloxy)carbonyl)amino)-3-phenylpropanamido)propanoate 
• 26054-99-9 N-Carbobenzoxy-L-asparaginyl-L-alanine tert-butyl ester 
• 92779-28-7 Z-Ile-Ala-O-t-Bu 
• 120008-73-3 4-[(R)-3-((S)-1-tert-Butoxycarbonyl-ethylamino)-3-ethoxycarbonyl-propyl]-piperidine-1-carboxylic acid benzyl ester 
• 120008-73-3 4-[(S)-3-((S)-1-tert-Butoxycarbonyl-ethylamino)-3-ethoxycarbonyl-propyl]-piperidine-1-carboxylic acid benzyl ester 
• 105259-96-9 tert-butyl-N-<(1R)-5-(1-benzyloxycarbonyl-4-piperidyl)-1-ethoxycarbonylpentyl>-L-alaninate 
• 105259-97-0 tert-butyl-N-<(1S)-5-(1-benzyloxycarbonyl-4-piperidyl)-1-ethoxycarbonylpentyl>-L-alaninate 
• 129389-21-5 N-<1(R)-ethoxycarbonyl-6-(1-benzyloxycarbonyl-4-piperidyl)hexyl>-L-alanine tert-butyl ester 
• 120008-77-7 N-<1(S)-ethoxycarbonyl-6-(1-benzyloxycarbonyl-4-piperidyl)hexyl>-L-alanine tert-butyl ester 
• 127462-50-4 (S)-2-{(R)-2-[((S)-2-tert-Butoxycarbonylamino-propionyl)-methyl-amino]-3-[4-(tert-butyl-dimethyl-silanyloxy)-phenyl]-propionylamino}-propionic acid tert-butyl ester 
• 82825-38-5 4-(Alaninocarbonyl)tetradecachlorotriphenylmethyl radical tert butyl ester 

Relevant articles and documents

Cyclic phosphoramidates as prodrugs of 2′-C-methylcytidine

The currently approved treatment for hepatitis C virus infections is a combination of Ribavirin and pegylated Interferon. It leads to a sustained virologic response in approximately only half of the patients treated. For this reason there is an urgent need of new therapeutic agents. 2′-C-Methylcytidine is the first nucleoside inhibitor of the HCV NS5B polymerase that was efficacious in reducing the viral load in patients infected with HCV. The application of a monophosphate prodrug approach based on unprecedented cyclic phosphoramidates is reported. Our SAR studies led to compounds that are efficiently converted to the active triphosphate in human hepatocytes.

Antiviral phosphoramidates

The invention provides novel nucleoside compounds of formula I wherein R1, R2a, R2b, R3, R4, R5, R6, R8a, R9 and R10 are as defined herein which are useful for the treatment of Hepatitis C Virus (HCV) mediated diseases. The invention further provides methods for treatment or prophylaxis of HCV mediated diseases with compounds of formula I and pharmaceutical compositions comprising these compounds,

Synthesis of optically active lipopeptide analogs from the outer membrane of Escherichia coli

The synthesis of optically active lipopeptide derivatives has been accomplished by the use of chiral glycerol derivatives. Lipopeptide derivatives with (R)-glycerol moieties showed higher mitogenic activities than those with the (S)-configuration. N-2,2,2-Trichloroethoxycarbonyl lipopeptide derivatives increased mitogenic activity.

Derivatives of 2,6-diamino-3-haloheptanedioic acid

This invention relates to amino acid, dipeptide and tripeptide derivatives of 2,6-diamino-3-haloheptanedioic acids, processes for preparing the same, and their use as antibacterial agents.